Stephen Marmaras: The Burden of High-Cost Biologics
Stephen Marmaras, director of policy and advocacy for the Global Healthy Living Foundation, discusses the burden of high-cost biologics.
Transcript:What’s the burden of out-of-pocket costs for patients who rely on biologic drugs?
I think from the patient perspective…there’s a big surprise for patients. I think we’ve seen a significant rise of high-deductible health plans, and a lot of people with chronic diseases purchasing those high-deductible health plans, in part, because the premiums associated with those high-deductible health plans are significantly lower. Patients have begun to rely on needing that high deductible with their copay assistance programs.
So, I think what we’re most afraid of, most recently with out-of-pocket costs regarding these specialty drugs, is that patients have come to rely on a way of getting by the high-deductible health plan that may be going away, and they may not be aware of that.
In our advocacy efforts, one of the things we’re working on is to educate patients that they really have to look into their health plan, especially their high-deductible health plans, and understand if copay accumulators are being applied to that policy.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market
November 9th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
April 12th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.
